Robert F. Friel and Donald J. Rosenberg were named independent directors of the company. The new appointments are effective Feb. 12, 2016. Here are five things to know about the new appointments:
1. Mr. Friel will be a member of the board’s compensation committee; Mr. Rosenberg will be a member of the board’s compensation committee and the nominating and corporate governance committee.
2. The NuVasive’s board is now nine directors, eight of which are independent directors.
3. Mr. Friel is the chairman, CEO and President of PerkinElmer and has more than 35 years of finance and operational experience. Mr. Rosenberg is executive vice president, general counsel and corporate security of Qualcomm.
4. Throughout his career, Mr. Friel has experience held several senior management positions with AlliedSignal — now Honeywell.
5. Mr. Rosenberg has experience in corporate governance, compliance, law department management, litigation, securities regulation, intellectual property and competition issues.
“As we continue to grow and mature as a company, their collective years of broad experience across important industries will add a valuable perspective to our company,” said NuVasive Chairman and CEO Gregory T. Lucier. “We appreciate their willingness to serve as directors and look forward to benefiting from their judgment and counsel.”
More articles on orthopedic devices:
Minimally invasive SI joint fusion could save $1,000s: 2 new studies
Wenzel Spine receives FDA clearance for VariLift-LX: 4 points
Medtech to present ROSA robotic surgery brain system at annual meetings: 3 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
